+

WO1990005537A1 - Inhib, un facteur qui inhibe les leukocytes actives par la cytokine - Google Patents

Inhib, un facteur qui inhibe les leukocytes actives par la cytokine Download PDF

Info

Publication number
WO1990005537A1
WO1990005537A1 PCT/US1989/004864 US8904864W WO9005537A1 WO 1990005537 A1 WO1990005537 A1 WO 1990005537A1 US 8904864 W US8904864 W US 8904864W WO 9005537 A1 WO9005537 A1 WO 9005537A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhib
molecule
inflammation
tnf
factor
Prior art date
Application number
PCT/US1989/004864
Other languages
English (en)
Inventor
David S. Silberstein
Majorie Minkoff
Original Assignee
Brigham And Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham And Women's Hospital filed Critical Brigham And Women's Hospital
Publication of WO1990005537A1 publication Critical patent/WO1990005537A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the identification and substantial purification of a factor (INHIB) that inhibits the immunologic activity of cyto ine-stimulated leukocytes.
  • the invention additionally relates to processes for preparing the INHIB molecule, methods of purifying the molecule, screening assays for the molecule, compositions containing INHIB, and uses for the molecule.
  • Levels of circulating leukocytes are elevated in conditions such as allergy, asthma, parasitic diseases, autoimmune disorders such as connective tissue disease, in certain types of cancer, and in patients undergoing therapy with interleukin-2 (IL-2) or granulocyte-macrophage colony- stimulating factor.
  • Leukocytes in particular eosinophils, persist in the circulation with a half-life of several hours to two days and then either enter the marginated (blood vessel wall) pool or infiltrate tissues. -At the site of inflammation in tissue, eosinophils and neutrophils, for example, secrete toxic substances that may kill infectious organisms but also may damage host (patient) tissues.
  • eosinophil cytotoxins cause ultrastructural damage and progressive fibrosis in the major organ systems, and ultimate ⁇ ly lead to death due to cardiac or respiratory arrest, or liver failure.
  • Uromodulin binds with high affinity to interleukin-1 (IL-1) and to TNF, suggesting that its activity is specific for cellular events mediated by these two factors.
  • This factor which inhibits the immunological activity of cytokine-stimulated leukocytes, in particular eosinophils and neutrophils.
  • This factor which suppresses proinflammatory functions, may be found in sera and various other biological tissues and fluids.
  • This factor consists of a single polypeptide species and has a molecular weight (MW) of approximately 70 kilodaltons. Its activity is destroyed by either heating at 80°C or by treatment with trypsin, demon ⁇ strating that it is a polypeptide.
  • the inventors discovered, during the course of molecular sizing HPLC, that the potency of INHIB increased.
  • INHIB When serum from a subject with allergic dermatitis was used as a source of INHIB, the HPLC increased the potency of INHIB by a factor of 50 to 2000 in multiple experiments. INHIB was also derived by HPLC fractionation of control serum from each of many other subjects, demonstrating that INHIB is a component of normal biological fluid and tissue that can be activated by purifica ⁇ tion and, presumably, by certain physiological events in vivo.
  • the present invention relates to INHIB as well as to its functional derivatives.
  • the invention additionally pertains to processes for preparing and purifying INHIB, screening assays for INHIB, diagnostic and therapeutic uses of INHIB, and compositions containing INHIB or its functional deriva ⁇ tives.
  • the invention includes INHIB or its functional derivatives, which are substantially free of natural contaminants.
  • the purification of INHIB was achieved by a sequence of protein fractionation methodologies. Following each separation step, the fractions were screened for the ability to inhibit eosinophil killing of targets in vitro. The fractions containing the major inhibitory activity were forwarded to the next separation methodology.
  • the invention includes a method for recovering INHIB in substantially pure form which includes, but is not limited to, the following steps:
  • step (g) recovering the filtrate obtained in step (f) in substantially pure form.
  • Purified and partially purified INHIB suppressed the killing of targets by eosinophils stimulated with granulocyte- macrophage colony-stimulating factor as well as with TNF. This demonstrates that the activity of INHIB is not cytokine- specific.
  • Purified and partially-purified INHIB suppressed the adherence of TNF-stimulated neutrophils to plastic surfaces. This demonstrates that the inhibitory activity of INHIB is not restricted to eosinophils but rather regulates a variety of inflammatory cell types.
  • the purification of INHIB also permits the generation of INHIB-related oligonucleotide and antibody probes that can be used to screen gene libraries for the molecular cloning of the INHIB gene.
  • culture medium containing biosynthetic (reco binant) INHIB would be a superior source material compared to natural biological tissues or fluids for the purification of INHIB.
  • the purification strategy presented here may be used to purify recombinant INHIB.
  • the invention includes the INHIB obtained by the above methods.
  • the invention further pertains to INHIB and its deriva ⁇ tives which are detectably labeled.
  • the invention is further directed to a method of diagnosing the presence and location of inflammation in a mammalian subject suspected of having an inflammation which comprises: (a) administering to said subject a composition containing a detectably labeled binding molecule (e.g., antibody) capable of binding and identifying INHIB; and (b) detecting said binding molecule.
  • a detectably labeled binding molecule e.g., antibody
  • the invention also pertains to a method of diagnosing the presence and location of an inflammation in a mammalian subject suspected of having an inflammation which comprises: (a) incubating a biological sample from said subject suspected of containing INHIB in the presence of a detectably labeled binding molecule (e.g., antibody) capable of identifying INHIB; and (b) detecting said binding molecule which is bound in said sample.
  • a detectably labeled binding molecule e.g., antibody
  • Said biological samples may include various tissues or body fluids such as blood serum, for example.
  • the invention is also directed to a method of treating inflammation in a mammalian subject which comprises providing to said subject in need of such treatment an amount of an anti-inflammatory agent sufficient to suppress said inflamma ⁇ tion; wherein said anti-inflammatory is selected from the group consisting of: INHIB, a fragment of INHIB, a chemical derivative of INHIB, a variant of INHIB, and an analogue of INHIB.
  • the invention also includes the above method for treating inflammation wherein said anti-inflammatory agent is adminis ⁇ tered in a suitable carrier.
  • the invention also relates to a pharmaceutical composi ⁇ tion for treating inflammation in a mammalian subject comprising administering an inflammation-reducing amount of an anti-inflammatory agent, wherein said agent is selected from the group consisting of: INHIB, a fragment of INHIB, a chemical derivative of INHIB, a variant of INHIB, and an analogue of INHIB.
  • an anti-inflammatory agent selected from the group consisting of: INHIB, a fragment of INHIB, a chemical derivative of INHIB, a variant of INHIB, and an analogue of INHIB.
  • the invention therefore includes novel methods for recovering and purifying the new INHIB molecule and its functional derivatives, uses for the molecule, including diagnosing and treating inflammation in a mammalian subject, and novel compositions containing INHIB or its functional derivatives.
  • FIG. 1 The failure of eosinophils from a human subject (NR) to respond with enhanced cytotoxic function to TNF.
  • Normal and NR eosinophils were purified and cultured in the presence of schistosomula targets, antibody, and either 100 U/ml or the indicated concentration of TNF.
  • the killing of schistosomula targets was scored in duplicate or triplicate by microscopy at 36 to 40 hours.
  • FIG. 3 The failure of NR neutrophils to respond with enhanced respiratory burst to TNF.
  • Neutrophils from a normal subject (A) and NR (B) were isolated and incubated in physiological buffer at 37° for 10 minutes with (solid circles) or without (open circles) 100 U/ml of TNF.
  • the neutrophils were treated with 50 ug/ml of IgG aggregates and incubated further at 37 ⁇ C.
  • the release of H2O2 over time was monitored by the scopoletin method. TNF alone did not stimulate the release of H2O2 (not shown).
  • Figure 4 Specific binding of ⁇ I-TNF to NR neutrophils (solid circles) and to normal neutrophils from 2 different subjects (open symbols). 3 x lO* *5 neutrophils were incubated overnight with either the indicated dose of labeled TNF (for total cpm bound) or that dose plus a 1000-fold excess of unlabeled TNF (for non-specific cpm bound). Non-specific cpm bound was subtracted from total cpm bound to determine the specific cpm bound at each concentration. At doses of less than 15 ng TNF/600ul , non-specific cpm bound were ⁇ 26% of total cpm. Figure 5. The ability of NR serum to cross-inhibit heterologous eosinophils from responding to TNF.
  • the cytotoxic function of eosinophils was assayed in the presence (squares) or absence (circles) of 100 U/ml of TNF.
  • Control heterologous serum (solid) or NR serum (open) was added to the cultures at the indicated concentrations.
  • the horizontal lines indicate the level of killing with no serum added in the presence (dashes) or absence (dots) of TNF.
  • FIG. 6 Variation over time in the ability of NR serum to inhibit the cytotoxic function of TNF-stimulated eosino ⁇ phils.
  • the cytotoxic function in the presence (100%) or absence (0%) of 100 U/ml of TNF was assayed.
  • Heterologous (with respect to the eosinophils) sera were added to the cultures at a concentration of 10%. Samples 1-4 were taken from control donors.
  • Figure 7 Population distribution of the inhibitory activity in human sera. 100 anonymous serum samples were obtained from the Red Cross and tested as in Fig. 6 for the ability to inhibit the cytotoxic function of TNF-activated eosinophils at a concentration of 10%.
  • NR serum 100 ul was injected on a TSK 400 column, and 1 ml fractions were collected. The fractions were heat-inactivated (56° for 30 minutes) and added to TNF- stimulated eosinophils at a concentration of 20%. The cytotoxic function of the eosinophils was determined at 36 to 40 hours.
  • Figure 9 Increase in the titer of INHIB as a con ⁇ sequence of HPLC sizing chromatography.
  • NR serum A, same sample as 8A
  • a human serum pool (lot 29309039, obtained from-- Flow Laboratories)
  • B a control serum sample with no inhibitory activity
  • C same sample as 8B
  • HPLC fractions 7 through 9 of these sera were tested for inhibitory activity in the eosinophil cytotoxicity assay at the indicated concentrations.
  • FIG. 10 Sensitivity of INHIB to heat or trypsin treatment.
  • the results in 3 experiments with INHIB from NR serum and 4 experiments with different control sera were essentially similar; in order to compare the results on the same scale, the level of killing in the presence of TNF with no inhibitors present was set equal to 100%. Values represent the mean % maximum killing ⁇ S.E. in 7 experiments.
  • FIG. II The inability of INHIB to protect L929 cells from TNF; time dependence of protection by the neutralizing monoclonal antibody 245-10E11. 100 U/ml of TNF was added to actinomycin D-treated (solid symbols) or untreated (open symbols) L929 cells. At the indicated times, 20% INHIB (circles, HPLC fractions 7 through 9) or 1000 neutralizing units of monoclonal antibody (triangles) was added to the cultures. The survival of cells was measured by the MTT method, and the relative protection by either of the inhibi ⁇ tors was calculated by comparison with the no inhibitor (0%) and no TNF (100%) control values.
  • FIG. 12 The existence of a serum factor (INHIB) that inhibits the cytotoxic function of TNF-stimulated human eosinophils.
  • Normal human serum solid symbols
  • serum from a subject with frequent episodes of allergic dermatitis open symbols
  • components 10 5 purified human eosinophils, antibody from Brazilian schistosomiasis patients, control medium [circles] or medium plus 100 U/ml of TNF [squares], and 100 mechanically transformed schistosomula
  • the killing of schisto ⁇ somula targets was scored by microscopy. Values represent the mean od duplicate determinations.
  • Figure 13 Molecular weight estimate of the INHIB in normal (solid circle) and allergic dermatitis (open circle) sera. 100 ul samples of serum were chromatographed on a TSK- 400 HPLC column with a solvent of Hank's Balanced Salt Solution (buffered with 25 M Hepes, pH 7.0, and containing penicillin and streptomycin). The eluted samples were tested in the eosinophil cytotoxicity assay, as described in Figure 12.
  • Figure 14 Increased potency of INHIB as a result of partial purification. Pooled fractions 17-19 from Figure 13 (squares) were compared for inhibitory activity to the sera (circles) from which they were derived. Samples from a normal (solid symbols) and allergic dermatitis subjects (open symbols) were tested at the indicated concentration in the eosinophil cytotoxicity assay, as described for Figure 12.
  • FIG 16. Enrichment of INHIB by chromatography over controlled-pore glass beads. Samples were generated as described in the text and assayed as described for Figure 12. The non-adherent runthrough (RT) usually contained some INHIB and could be recycled through the column.
  • RT non-adherent runthrough
  • FIG 17. Enrichment of INHIB by hydrophobic inter ⁇ action chromatography.
  • the active fraction from Figure 16 was chromatographed as described in the text. The elution of proteins was monitored by absorbance at 280 nm (top figure, fraction numbers indicated). After dialysis in medium, aliquots of these fractions were tested in the eosinophil cytotoxicity assay, as described for Figure 12 (bottom figure).
  • Figure 18 Enrichment of INHIB by anion exchange chromatography. The active fraction from Figure 17 was chromatographed as described in the text. The elution profiles and biological activities were determined as described for Figure 17.
  • FIG 19. Final purification of INHIB by reversed-phase HPLC.
  • the active fraction from Figure 18 was chromatographed as described in the text.
  • the elution profiles and biological activities were determined as for Figure 17, except that the results represent the mean of two experiments.
  • the range of 0-100% is equal to the difference between the negative control and the maximum killing.
  • the arrow shows the peak of purified INHIB.
  • FIG 20 SDS-poIyacrylamide gel analysis of purified INHIB. The fraction numbers, corresponding to Figure 19 and the positions of molecular weight markers, are shown. The single species of purified INHIB is indicated by an arrow.
  • Figure 21 The ability of purified INHIB to inhibit neutrophil adherence to plastic.
  • the samples from Figure 19 were tested in two experiments as described in the text. The range of 0-100% is equal to the difference between the negative control and maximum adherence, assayed in duplicate in each of two experiments. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • One aspect of the present invention relates to the discovery of a natural inhibitor of cytokine-stimulated leukocyte immunological activity, referred to as INHIB.
  • the invention is directed toward substantially pure INHIB and its "functional derivatives.”
  • leukocyte refers to white blood cells, including neutrophils, eosinophils, and monocytes.
  • activated activation
  • immunological activity the stimulation of subject cells to behave in a certain biologically expected manner, i.e., for neutro ⁇ phils to become adherent or eosinophils to become cytotoxic, for example.
  • cytokine refers to a compound capable of activating leukocytes, in particular, eosinophils and neutrophils.
  • Cytokines are, in general, proteins or glyco- proteins having a molecular weight of 10-100 kDa. Examples of cytokines are disclosed by Stephenson (In: Animal Cell Biotechnology. Vol. 2, Spier, R.E., et al .. eds., Academic Press, pp. 41-45 (1985)).
  • cytokine any compound capable of regulating INHIB inhibition of the immunological activities of leukocytes, such as cytotoxicity or adherence, may be employed in accordance with the present invention
  • cytokine it is preferable to employ a cytokine, and it is especially preferable to employ the cytokine TNF or granulocyte-macrophage colony-stimul ting factor (GMCSF), or eosinophil cytotoxic enhancing factor (ECEF) and their recombinant forms.
  • GMCSF granulocyte-macrophage colony-stimul ting factor
  • ECEF eosinophil cytotoxic enhancing factor
  • a “fragment” of a molecule such as INHIB is meant to refer to any polypeptide subset of that molecule.
  • a “variant” of a molecule such as INHIB is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof.
  • An “analogue” of a molecule such as ' INHIB is meant to refer to a non-natural molecule substantially similar to either the entire molecule or a fragment thereof.
  • a molecule is said to be "substantially similar” to another molecule if the sequence of amino acids in both molecules is substantially the same, and if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical.
  • a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half-life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Examples of moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980) and will be apparent to those of ordinary skill in the art.
  • One screening method for determining whether a given compound is an INHIB functional derivative comprises, for example, immunoassays employing RIA or ELISA methodologies, based on the production of specific neutralizing antibodies (monoclonal or polyclonal) to natural INHIB.
  • Other suitable screening methods will be readily apparent to those of skill in the art.
  • the INHIB molecule disclosed herein is said to be "substantially free of natural contaminants" if preparations which contain it are substantially free of materials with which this product is normally and naturally found.
  • preferred methods of purification include, without being limiting, the following steps: a) Fractionating the biological sample containing INHIB based on precipitating proteins at high ionic strength. Proteins differ in their solubility in concentrated salt solutions and hence can be separated from one another by precipitation at high ionic strength.
  • the preferred salt is ammonium sulfate, although other salts are known and may be used.
  • DEAE-cellulose-exchange chromatography may be used.
  • affinity chromatography such as affi-blue gel affinity chromatography could be used at this step.
  • purified INHIB fragments or its derivatives manufactured using organic synthesis or recombinant DNA techniques, or by proteolysis.
  • step (b) instead of using chromatography over controlled-pore glass beads in step (b), one could equally use affi-blue gel chromatography to remove serum albumin from a serum sample containing INHIB. (See Travis et al.. Biochem. J. 157:301-306 (1976); Yip et al .. PNAS 78:1601).
  • the term “mammal” is intended all mammals in which INHIB may be obtained from tissue or fluid and for which the inhibition of eosinophilic or neutrophilic immunologic activity, for example, and other uses of the present inven ⁇ tion, described below, have a beneficial effect. Foremost among such mammals are humans; however, the invention is not intended to be so limiting, it being within the contemplation of the invention to treat any and all mammals which may experience the beneficial effects of the invention.
  • the present invention also includes methods of detecting INHIB or its functional derivatives in a sample or subject.
  • antibodies specific for INHIB, or its functional derivatives may be detectably labeled with any appropriate ligand, for example, a radioisotope, an enzyme, a fluorescent label, a paramagnetic label, or a free radical.
  • ligand for example, a radioisotope, an enzyme, a fluorescent label, a paramagnetic label, or a free radical.
  • the presence of inflammation may be detected through the use of such detectably labeled materials.
  • Methods of making and detecting such detectably labeled antibodies or their functional derivatives are well known to those of ordinary skill in the art.
  • antibody refers to monoclonal or monospecific antibodies which have a substantially homogeneous population of molecules.
  • Monoclonal antibodies directed toward INHIB may be obtained by methods known to those skilled in the art. See, for example, Kohler and Milstein, Nature 256:495-497 (1975) and U.S. Patent No. 4,376,110. These publications, as well as those mentioned hereunder, are incorporated herein by reference. Unless defined otherwise, various terms used herein have the same meaning as is well understood in the art to which the invention belongs.
  • antibody is also meant as well to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')2 > which are capable of binding to antigen.
  • antibodies or their functional derivatives, to detect or diagnose the presence and location of an inflammation in a mammalian subject suspected of having an inflammation by utilizing an assay for INHIB, comprising incubating a biological sample from said subject suspected of containing INHIB in the presence of a detectably labeled binding molecule (e.g., antibody) capable of identifying INHIB, and detecting said binding molecule which is bound in a sample.
  • a detectably labeled binding molecule e.g., antibody
  • a biological sample may be treated with nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble protein.
  • the support may then be washed with suitable buffers followed by treatment with the detectably labeled INHIB-specific antibody.
  • the solid phase support may then be washed with the buffer a second time to remove unbound antibody.
  • the amount of bound label on the antibody may then be detected by conventional means.
  • One embodiment for carrying out the assay of the present invention on a sample containing INHIB comprises:
  • step (d) separating the solid phase support from the incubation mixture obtained in step (c);
  • This aspect of the invention relates to a method for detecting INHIB or fragment thereof inr a sample comprising
  • the specific concentrations of detectably labeled antibody and INHIB, the temperature and time of incubation, as well as other assay conditions may be varied, depending on various factors including the concentration of INHIB in the sample, the nature of the sample, and the like.
  • the binding activity of a given lot of antibody directed toward INHIB may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • the INHIB-specific antibody can be detectably labeled is by linking the same to an enzyme.
  • This enzyme when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluoro etric or by visual means.
  • Enzymes which can be used to detectably label the INHIB-specific antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetyl- choline esterase.
  • the INHIB-specific antibody may also be labeled with a radioactive isotope which can be determined by such means as the use of a gamma counter or a scintillation counter or by audioradiography.
  • Isotopes which are particularly useful for the purpose of the present invention are: 3 H, ---- ⁇ 1 , ⁇ * ⁇ • I, 35 S, 14 C, and 51 Cr. It is also possible to label the INHIB-specific antibody with a fluorescent compound. When the fluorescent! labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to the fluorescence of the dye.
  • fluorescent labelling compounds include fluorescein isothiocyanate, rhodamine, phycoerytheri n , phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • the INHIB-specific antibody can also be detectably labeled using fluorescence emitting metals such as ⁇ Eu, or others of the lanthanide series. These metals can be attached to the INHIB-specific antibody using such metal chelating groups as di ethyl enetri ami nepentaacetic acid (DTPA) or ethyl enedi ami netetraacetic acid (EDTA).
  • DTPA di ethyl enetri ami nepentaacetic acid
  • EDTA ethyl enedi ami netetraacetic acid
  • the INHIB-specific antibody also can be detectably labeled by coupling it to a chemi luminescent compound. The presence of the chemi luminescent-tagged INHIB-specific antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemi luminescent labeling compounds are lu inol, isoluminol, theromatic acridinium ester, imidazole, acridiniu salt and oxalate ester.
  • a bi luminescent compound may be used to label the INHIB-specific antibody of the present invention.
  • Bioluminescence is a type of chemi luminescence found in biological systems in which a catalytic protein increases the efficiency of the chemi luminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
  • Important bioluminescent compounds for purposes of labeling are luciferin, lucif erase and aequorin.
  • Detection of the INHIB-specific antibody may be accom ⁇ plished by a scintillation counter, for example, if the detectable label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorescent material.
  • the detection can be accomplished by colori etric methods which employ a substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
  • the detection of foci of such detectably labeled antibodies is indicative of a site of inflammation.
  • this examination for inflamma ⁇ tion is accomplished by removing samples of tissue or blood and incubating such samples in the presence of detectably labeled antibodies.
  • this technique is accomplished in a non-invasive manner through the use of magnetic imaging, fluorography, etc.
  • a diagnostic test may be employed in monitoring organ transplant recipients for early signs of potential tissue rejection.
  • Such assays may also be conducted in efforts to determine a subject's clinical status in rheumatoid arthritis and other chronic inflammatory diseases.
  • INHIB is involved in inflammatory processes.
  • the term "inflammation” is meant to include reactions of both the specific arid non-specific defense systems.
  • a specific defense system reaction is a specific immune system reaction response to an antigen.
  • Examples of a specific defense system reaction include the antibody response to antigens such as rubella virus, and delayed-type hypersensitivity response mediated by T-cells (as seen, for example, in individuals who test "positive” in the Mantaux test).
  • a non-specific defense system reaction is an inflammatory response mediated by leukocytes incapable of immunological memory. Such cells include granulocytes, macrophages, neutrophils, eosinophils, etc. Examples of a non-specific defense system reaction include the immediate swelling at the site of a bee sting, the reddening and cellular infiltrate induced at the site of a burn, and the collection of poly- morphonuclear (PMN) leukocytes at sites of bacterial infection (e.g., pulmonary infiltrates in bacterial pneumonias, pus formation in abscesses).
  • PMN poly- morphonuclear
  • the present invention will be easily adapted to the diagnosis, monitoring, and treatment of inflammatory disease processes such as rheumatoid arthritis, acute and chronic inflammation, post-ischemic (reperfusion) leukocyte-mediated tissue damage, acute leukocyte-mediated lung injury (e.g., Adult Respiratory Distress Syndrome), and other tissue- or organ-specific forms of acute inflammation (e.g., glomerulonephritis).
  • inflammatory disease processes such as rheumatoid arthritis, acute and chronic inflammation, post-ischemic (reperfusion) leukocyte-mediated tissue damage, acute leukocyte-mediated lung injury (e.g., Adult Respiratory Distress Syndrome), and other tissue- or organ-specific forms of acute inflammation (e.g., glomerulonephritis).
  • treatment is meant to include the prevention, elimination and attenuation or amelioration of the conditions of pathology described below.
  • the therapeutic effects of INHIB may be obtained by providing to a patient the entire INHIB molecule, or any therapeutically active peptide fragment thereof.
  • the therapeutic advantages of INHIB may be augmented through the use of INHIB mutants or variants possessing additional amino acid residues added to enhance its coupling to a carrier or to enhance the activity of INHIB.
  • the scope of the present invention is further intended to include mutant forms of INHIB (including INHIB molecules which lack certain amino acid residues, or which contain altered amino acid residues, so long as such mutant INHIB molecules exhibit the capacity to affect cellular function).
  • the INHIB molecule of the present invention and its functional derivatives can be formulated according to known methods of preparing pharmaceutically useful compositions, whereby these materials or their functional derivatives are combined in a mixture with a pharmaceutically acceptable carrier vehicle.
  • compositions comprising INHIB when administered in said suitable pharmaceutically acceptable (sterile and non-toxic) carrier to mammals suffering from inflammatory disease conditions, cancer, or the like.
  • suitable pharmaceutically acceptable carrier sterile and non-toxic
  • suitable pharmaceutically acceptable carrier sterile and non-toxic
  • Suitable vehicles and their formulation are described, for example, in Remington's Pharmaceutical Sciences (16th ed., Osol , A., Ed., Mack, Easton, PA (1980)).
  • compositions will contain a thera ⁇ Therapeuticically effective amount of INHIB molecule, or its functional derivatives (an inflammation-reducing amount), together with a suitable amount of carrier vehicle.
  • compositions and preparations of the present invention mediate suppression of, attenuate, or ameliorate inflammation, if, when provided to an animals, their administration results in either a decrease in the inflammation or prevalence of inflammation-associated cells. It is to be understood that the compositions and preparations of the present invention are to be provided to an animal in amounts and at frequencies capable of successfully mediating the suppression of said inflammation. The proper amounts and frequences will be readily discernable to those of skill in the art.
  • compositions within the scope of this invention include all compositions wherein each of the components thereof is contained in an amount effective to achieve its intended purpose.
  • Suitable pharmaceutically acceptable carriers may comprise excipients and auxiliaries which facilitate process ⁇ ing of the active compounds into preparations which can be used pharmaceutically.
  • a preferred product of the invention is a sterile pharmaceutical composition for therapeutic use containing INHIB or its functional derivatives, which is suitable for intravenous administration.
  • the product may be in lyophilized form to be reconstituted for use by addition of a suitable carrier, or diluent, or it may be in the form of an aqueous solution.
  • a sterile diluent which may contain materials generally recognized for approximating physiological conditions and/or as required by governmental regulation.
  • the sterile diluent may contain a buffering agent to obtain a physiologically acceptable pH, such as sodium chloride, saline, phosphate-buffered saline, and/or other substances which are physiologically acceptable and/or safe for use.
  • a physiologically acceptable pH such as sodium chloride, saline, phosphate-buffered saline, and/or other substances which are physiologically acceptable and/or safe for use.
  • the material for intravenous injection in humans should conform to regulations established by the Food and Drug Administration, which are available to those in the field.
  • the pharmaceutical composition may also be in the form of an aqueous solution containing many of the same substances as described above for the reconstitution of a lyophilized product.
  • the products of the invention may be incorporated into pharmaceutical preparations which may be used for therapeutic purposes.
  • pharmaceutical preparation is intended in a broader sense herein to include preparations containing a protein composition in accordance with this invention, used not only for therapeutic purposes but also for reagent or diagnostic purposes as known in the art, or for tissue culture.
  • the pharmaceutical preparation intended for therapeutic use should contain a "pharmaceutically acceptable” or “therapeutically effective amount” of INHIB, i.e., that amount necessary for preventative or curative health measures. If the pharmaceutical prepara ⁇ tion is to be employed as a reagent or diagnostic, then it should contain reagent or diagnostic amounts of INHIB.
  • a composition is said to be “pharmaceutically acceptable” if its administration can be tolerated by a recipient patient.
  • Such an agent is said to be administered in a “therapeutically effective amount” if the amount administered is physiological ⁇ ly significant.
  • An agent is "physiologically significant” if its presence results in a detectable change in the physiology of a recipient patient.
  • one unit of INHIB activity will produce 50% inhibition of cytokine-activated eosinophil cytotoxicity or neutrophil adherence at an eosinophil concentration of 2 x 10 6 cells/ml and a neutrophil concentration of 2 x 10 6 cells/ml in a standardized in vitro assay system.
  • INHIB at a concentration of 20 U/ml produces a maximal inhibition of 100% at the same cell concentration.
  • the therapeutic and/or diagnostic dosage administered will be dependent upon the particular inflammatory condition involved and may be dependent upon the age, weight, height, sex, general medical condition, and kind of concurrent treatment, if any, of the mammalian subject.
  • Methods useful for administering the molecules of the present invention include topical, subcutaneous, intra- articular, intraperitoneal , intrapleural , or intraocular.
  • the administration may be by continuous infusion, or by single or multiple boluses.
  • the effective molecule useful in the methods of the present invention may be employed in such forms as, for example, sterile suspensions for injection or encapsulated for targeting to specific tissue sites with antibodies directed to inflammation-related cell surface structures.
  • Controlled release prepara ⁇ tions may be achieved through the use of polymers to complex or absorb INHIB or its functional derivatives.
  • the controlled delivery may be achieved by selecting appropriate macro- molecules (for example, polyesters, polyamino acids, poly- vinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the appropriate concentration of macromolecu!es as well as the methods of incorporation, in order to control release.
  • Another possible method useful in controlling the duration of action by controlled release preparations is incorporation of the INHIB molecule or its functional derivatives into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(l ctic acid), or ethylene vinylacetate copolymers.
  • a polymeric material such as polyesters, polyamino acids, hydrogels, poly(l ctic acid), or ethylene vinylacetate copolymers.
  • microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatine-microcapsules and pol -(methylmethacylate) micro- capsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in acroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules
  • TNF tumor necrosis factor
  • a concentration of 100 U/ml the optimal dose for the eosinophil cytotoxicity assay (Silberstein et al .. Proc. Natl . Acad. Sci . USA 83:1055 (1986).
  • purified monoclonal antibody 245-10E11 Fendly et al . Hvbridoma 6:359 (1987) was used to neutralize the activity of TNF.
  • the neutralizing titer of the antibody was determined by the L929 cell cytotoxicity assay (Wang et al .. Science 228:149 (1985)).
  • GM-CSF was used at a final concentra ⁇ tion of 20 pM, the optimal dose in the eosinophil cytotoxicity assay (Silberstein et al .. J. Immunol. 137:3290 (1986)).
  • TNF was radioiodinated using IODO-BEADS (Pierce Chemical Co.). Autoradiography of 125 I-TNF following SDS-PAGE showed that the iodinated protein and the unlabeled TNF migrated in the same fashion. The majority (50-100%) of the initial bioactivity was recovered, as determined by the L929 cytotoxicity assay (Wang et al . , Science 228:149 (1985)). The specific activity of the labeled TNF was 0.7-7 X 10 8 cpm/ug (0.71-7.1 mCi/uM).
  • Venous blood was obtained from laboratory personnel for the preparation of serum, eosinophils and neutrophils. Some of the donors for eosinophil studies had moderately elevated eosinophil counts in association with allergies and/or asthma (total eosinophil counts ranged from 1 to 18% of total leukocytes for these studies).
  • a human subject (NR) was identified whose eosinophils and neutrophils were uniquely (in a study population of 38) unresponsive to TNF in immunological assays in vitro. Serum from this subject and 5 of 122 other subjects tested, inhibited eosinophil cytotoxic function in a dose-dependent manner.
  • Antibody Antibody to schistosomula of the human blood fluke S A mansoni was obtained from Brazilian schistosomiasis patients, as described previously (Silberstein et al ., Proc. Natl. Acad. Sci. USA 83:1055 (1986)).
  • Heparinized blood for the preparation of eosinophils was processed by a sequence of dextran sedimentation and discon- tinuous metrizamide density gradient centrifugation (Vadas et al ., J. Immunol. 122:1228 (1979)).
  • the purity of eosinophil preparations ranged from 80 to 99%.
  • Heparinized blood for the preparation of neutrophils was processed by a sequence of dextran sedimentation and Ficoll- Hypaque centrifugation (Boyum et al . Scand. J. Clin. Lab. Invest. 21 (SUPPI . 971:77 (1968)). Erythrocytes were removed by hypotonic lysis. The neutrophil preparations were essentially free of mononuclear cells and contained ⁇ 10% eosinophils.
  • Eosinophils were washed two times and suspended at a concentration of 2 X 10 6 /n ⁇ l in assay medium (minimal essential medium with Earle's salts, supplemented with 25 mM HEPES, 2 mM glutamine, 100 U/ml penicillin G, 100 ug/ml streptomycin, and 10% heat-inactivated fetal calf serum, all from GIBC0, Grand Island, NY).
  • assay medium minimal essential medium with Earle's salts, supplemented with 25 mM HEPES, 2 mM glutamine, 100 U/ml penicillin G, 100 ug/ml streptomycin, and 10% heat-inactivated fetal calf serum, all from GIBC0, Grand Island, NY.
  • the plates were incubated for 30 minutes at 37°C in a sealed, humidified box. After this period, 50 ul each of antibody and schistosomula were added, and the plates were incubated at 37 ⁇ C in a sealed, humidified box.
  • the contents of microwells were transferred to 12 x 75 mm polypropylene tubes, diluted with 5 ml of medium, and centrifuged at 500 g for 5 minutes. The supernatant was aspirated, and the eosinophils and schistosomula in the pellet were recultured in 250 ul of assay medium with fresh inhibitor and cytokine.
  • the killing of schistosomula was scored by microscopy at approximately 40 hours, using uptake of toluidine blue and lack of motility as indications of death.
  • the death of cultured schistosomula was negligible when either antibody or eosinophils was absent from the cultures.
  • neutrophils were suspended at a concentration of 10 ⁇ cells/200 ul of assay medium in the presence or absence of 100 U/ml TNF and allowed to settle in round-bottomed microtiter wells at 37°C for 2 hours. After this period, the adherence of neutrophils to the plastic surface was assayed by one of two methods. As described previously (Silberstein et al . Proc. Natl . Acad. Sci . USA 83:1055 (1986); Arnaout et al . J. Clin. Invest. 78:597 (1986)), the wells were examined using an inverted microscope. In the absence of TNF, there was very little adherence of neutrophils to the plastic, and most of the cells were in a pellet at the bottom of the wells. Usually, in the presence of TNF, neutrophils were seen covering the sides of the wells.
  • non-adherent neutrophils were washed away with warm saline, and a solution containing 0.1% Triton X-100, 0.4 mM 2-2' azino-di-3-ethyl-benzthiazoline-6-sulfonate plus 0.003% hydrogen peroxide in pH 4.0, 0.05 M sodium citrate substrate was added to the wells.
  • the generation of colored substrate was dependent on the quantity of neutrophil yeloperoxidase in the wells.
  • purified INHIB is also able to suppress neutrophil functions and other leukocyte functions related to inflammation.
  • H2O2 Production of H2O2 was measured by a modification of the method of Root et al . fJ. Clin. Invest. 55:945 (1975)). Purified cells were washed and resuspended in buffer (4 mM sodium phosphate, pH 7»4, 128 mM sodium chloride, 12 mM potassium chloride, 1 mM calcium chloride, 2 mM magnesium chloride, and 2 mM glucose) at a concentration of 10 6 /ml .
  • buffer 4 mM sodium phosphate, pH 7»4, 128 mM sodium chloride, 12 mM potassium chloride, 1 mM calcium chloride, 2 mM magnesium chloride, and 2 mM glucose
  • the cells were then placed in a cuvette (10 x 10 x 48 mm acrylic, Sarstedt, Princeton, NJ) with 5 ul of horseradish peroxidase stock (6.25 mg/ml buffer, Sigma), 10 ul of scopoletin stock (1 mM in buffer, Sigma), 10 ul of control buffer or TNF (for some experiments), and maintained at 37 ⁇ C. Fluorescence was monitored at 460 nm (with excitation at 350 nm) by a Perkin- Elmer model MPF-44B fluorescent spectrophoto eter (Perkin- Elmer, Norwalk, CT).
  • IgG aggregates were prepared by known methods. Chromato- graphically purified human IgG (Organon Teknika-Cappel) was dissolved in H2O2 assay buffer at a concentration of 10 mg/ml. This solution was heated in a water bath at 62 ⁇ C for 25 minutes. Control preparations of IgG that were not heat- aggregated did not stimulate detectable production of H2O2 by eosinophils or neutrophils.
  • TNF-sensitive L929 cell line The biological activity (expressed in units) of TNF was assayed as described (Wang et al . Science 228:149 (1985)), using the TNF-sensitive L929 cell line.
  • the cells were cultured either with 1 ug/ml actino ycin D for 16 hours (seeded initially at 10 5 cells/microwell) or without actino ⁇ mycin D for 28 hours (seeded originally at 2 x 10 ⁇ cells/- icrowell).
  • the viability of L929 cells was determined by the spectrophotometric measurement of the reduction of the tetra- zolium salt MTT (3-4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide) to for azan by the mitochondrial enzyme succinate dehydrogenase, a reaction which occurs only in living cells (Denizot et al . J. Immunol. Meth. 89:271 (1986)).
  • Ammonium sulfate precipitation Serum was brought to 50% saturation with ammonium sulfate (29.1 g/100 ml) and mixed for 24 to 48 hours at 4°C. The slurry was centrifuged at approximately 10,000 x g for 15 minutes. The resulting pellet (50P) was saved. The supernatant (50S) was brought to 65% saturation (addition of 9.2 g ammonium sulfate/100 ml). This was mixed in the cold and centrifuged as before. The resulting supernatant (65S) was saved. The pellet (65P) contained INHIB ( Figure 15), and was dialyzed in phosphate- buffered saline (PBS) for the next purification step.
  • PBS phosphate- buffered saline
  • Reversed-phase HPLC The pooled fractions were loaded on a Vydac C4 column (4.6 x 250 mm, the Nest Group, Southboro, MA). The column was washed with solution E (0.1% trifluoroacetic acid) for 20 minutes and eluted with a 30 minute gradient from solution E to solution F (0.1% trifluoro ⁇ acetic acid plus 50% acetonitrile). INHIB was recovered in fraction 40, corresponding to the indicated peak ( Figure 19).
  • Affi-Gel Blue (Bio-Rad) fractionation of ammonium sulfate-precipitated human serum was also utilized in place of step (2), chromatography over controlled-pore glass beads. This step also greatly enhanced INHIB activity in the serum albumin-reduced fraction (greater than 100%) as assessed by the eosinophil cytotoxicity assay and neutrophil adherence assay. There was some remaining activity in the albumin fraction which was not removed. (See Travis et al.. Bio- che . J. 157:301-306 (1976); Yip et al .. PNAS 78:1601) .
  • INHIB did not have detectable toxic effects on eosino ⁇ phils.
  • the presence of INHIB did not affect the uptake of trypan blue by eosinophils incubated in assay medium for periods up to 36 hours (not shown).
  • the presence of INHIB did not affect the uptake of trypan blue by non- adherent eosinophils removed from cytotoxicity cultures.
  • eosinophils incubated in medium with INHIB for 1 or 12 hours synthesized H2O2 at the same rate a control incubated eosinophils, following stimulus with an optimal dose of phorbol myristate acetate (PMA).
  • PMA phorbol myristate acetate
  • PMA increased the rate of H2O2 production by a factor 63.5 and 66.3 for eosinophils incubated 12 hours with and without an optimal dose of INHIB, while the increase was by a factor of only 30.3 after a 5 minute preincubation with 0.01% sodium azide.
  • the inventors also investigated the question of the effects of INHIB as specific for TNF stimulation of eosino ⁇ phils or whether INHIB would also suppress the function of GM- CSF-stimulated eosinophils.
  • Selected control sera #s 51, 52, 53, and 54 from the Red Cross collection, see Table 2) and various control HPLC sizing fractions (not shown) had no effect on the cytotoxic function of GM-CSF-stimulated eosinophils.
  • NR serum, chromatographical- ly-pur*ified INHIB from NR serum, and selected samples with detectable INHIB is 25, 33, 41, and 67) all reduced by the cytotoxic function of GM-CSF-stimulated eosinophils (Table 2).
  • samples 51 through 54 were selected for the absence of an inhibitory activity; samples 25, 33, 41 and 67 were selected for the presence of inhibitory activity (see Fig. 7).
  • INHIB did not protect L929 cells from the toxic effects of TNF either in the presence or absence or actinomycin D, when added to the culture after various times of incubation.
  • the TNF-specific monoclonal antibody 245-10E11 protected the L929 cells when added early in the culture period (Fig. II).
  • Purified INHIB can be employed as a therapeutic agent in immunologic disease in mammals, particularly diseases in which suppression of inflammation would be helpful.
  • purified INHIB may be employed for the treatment of cancers, viral and other infectious diseases, autoimmune diseases, for the correction of immune-deficiency diseases, and the like.
  • Purified INHIB could be used to generate antibodies as described, and to predict the structure of oligonucleotide probes; these reagents could be used to screen cDNA libraries for the isolation of the gene encoding INHIB.
  • the purifica ⁇ tion method, or some of its components, could be used on * a larger scale for the purification of biosynthetic (recom ⁇ binant) INHIB.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention décrit une molécule (l'INHIB) qui inhibe l'activité immunologique du leukocyte, des procédés de préparation et de purification de ladite molécule, un test de triage, des compositions contenant l'INHIB, ainsi que l'utilisation de la molécule pour les diagnostics et les thérapies.
PCT/US1989/004864 1988-11-16 1989-11-01 Inhib, un facteur qui inhibe les leukocytes actives par la cytokine WO1990005537A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27186388A 1988-11-16 1988-11-16
US271,863 1988-11-16

Publications (1)

Publication Number Publication Date
WO1990005537A1 true WO1990005537A1 (fr) 1990-05-31

Family

ID=23037411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004864 WO1990005537A1 (fr) 1988-11-16 1989-11-01 Inhib, un facteur qui inhibe les leukocytes actives par la cytokine

Country Status (2)

Country Link
AU (1) AU4752790A (fr)
WO (1) WO1990005537A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027098A3 (fr) * 1997-11-21 1999-11-18 Genentech Inc Antigenes apparentes a a33 et leurs utilisations pharmacologiques
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7198917B2 (en) 1997-11-21 2007-04-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US9234024B2 (en) 2008-05-06 2016-01-12 Genentech, Inc. Affinity matured CRIg variants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 110, 1989, SILBERSTEIN et al.: "Activation of eosinophils in cancer patients treated with IL-2 and IL-2 generated lymphokine- activated Killer cells", See Abstract No. 152536g, J. IMMUNOL., 142(6), 1989, p. 2162-7. *
CHEMICAL ABSTRACTS, Vol. 111, 1989, SILBERSTEIN et al.: "Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide", See Abstract No. 113461e, J. IMMUNOL., Vol. 143(3), 1989, p. 979-83. *
IMMUNOLOGY, Vol. 63, 1988, LIN et al.: "Inhibition of tumour necrosis factor and natural Cytotoxic cell lytic activities by a spleen cell-elaborated factor", pages 663-668. See Abstract and page 665, column 2, first full paragraph. *
J. EXP. MED., Vol. 167, April 1988, SECKINGER et al.: "A human inhibitor of tumor necrosis factor", pages 1511-1516. See Abstract and page 1516, lines 1-5. *
JOURNAL OF IMMUNOLOGY, Vol. 140, 01 March 1988, LAMAS et al.: "Studies on the adhesive interaction between purified eosinophils and cultured vascular endothelial cells", pages 1500-1505. See Abstract. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027098A3 (fr) * 1997-11-21 1999-11-18 Genentech Inc Antigenes apparentes a a33 et leurs utilisations pharmacologiques
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US6838554B2 (en) 1997-11-21 2005-01-04 Genetech, Inc. Nucleic acids encoding proteins that stimulate the proliferation of t-lymphocytes
US7115713B2 (en) 1997-11-21 2006-10-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7198917B2 (en) 1997-11-21 2007-04-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7211400B2 (en) 1997-11-21 2007-05-01 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7273726B2 (en) 1997-11-21 2007-09-25 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US9234024B2 (en) 2008-05-06 2016-01-12 Genentech, Inc. Affinity matured CRIg variants

Also Published As

Publication number Publication date
AU4752790A (en) 1990-06-12

Similar Documents

Publication Publication Date Title
Sarfati et al. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia
US6368788B1 (en) Method of treating complications in immunodepressed states resulting from HIV infection
Dale et al. Effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) on neutrophil kinetics and function in normal human volunteers
JP3288042B2 (ja) 細胞間接着分子−３およびその結合リガンド
US6344443B1 (en) Peptide antagonists of tumor necrosis factor alpha
US6051415A (en) Methods and kits for stimulating production of megakaryocytes and thrombocytes
US5770576A (en) Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
CA1337642C (fr) Facteur de chimiotactisme des neutrophiles, adn-c clone et anticorps monoclonaux se fixant a ce facteur
US5766593A (en) Anti-inflammatory CD14 peptides
EP0429542B1 (fr) Inhibiteur d'adhesion de leucocytes
Shiozawa et al. A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients
WO1990005537A1 (fr) Inhib, un facteur qui inhibe les leukocytes actives par la cytokine
US5252556A (en) Fragment capable of binding anti-CD43 autoantibodies
US5807830A (en) Method for treatment of purulent inflammatory diseases
Najjar Molecular basis of familial and acquired phagocytosis deficiency involving the tetrapeptide, Thr-Lys-Pro-Arg, tuftsin
US5322838A (en) Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation
US8153592B2 (en) Modulating toll-like receptor activity
WO1995003067A1 (fr) Agents pharmaceutiques a activite immunomodulatrice
Tsokos et al. Regulation of immunoglobulin secretion by factor H of human complement
US4861754A (en) Bacteriocins and compositions thereof in anti-viral treatment
WO1991008483A1 (fr) Il-8 a derivation endotheliale
US6524591B1 (en) Monocyte locomotion inhibitory factor
WO1992014757A1 (fr) Molecules d'adhesion cellule endotheliale-monocyte
CA2072626A1 (fr) Medicament liberant du cd14
Silberstein et al. A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载